Published in Adv Drug Deliv Rev on September 17, 2010
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem (2011) 1.17
Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol (2012) 1.13
Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics (2014) 1.01
Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci (2011) 0.97
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. Am J Nucl Med Mol Imaging (2014) 0.88
Strain-Promoted Catalyst-Free Click Chemistry for Rapid Construction of (64)Cu-Labeled PET Imaging Probes. ACS Med Chem Lett (2012) 0.87
64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol (2012) 0.87
Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol Imaging Biol (2012) 0.84
Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets (2015) 0.84
Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. Radiochim Acta (2012) 0.84
Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin αvβ₆. Bioorg Med Chem (2011) 0.83
Development of a new thiol site-specific prosthetic group and its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas. Bioconjug Chem (2013) 0.81
A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol (2013) 0.80
Development of a clickable bimodal fluorescent/PET probe for in vivo imaging. EJNMMI Res (2015) 0.80
Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer. Sci Rep (2015) 0.79
PET probes beyond (18)F-FDG. J Biomed Res (2014) 0.79
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol (2014) 0.78
The Effect of Bi-Terminal PEGylation of an Integrin αvβ₆-Targeted ¹⁸F Peptide on Pharmacokinetics and Tumor Uptake. J Nucl Med (2015) 0.78
Pretargeted Positron Emission Tomography Imaging That Employs Supramolecular Nanoparticles with in Vivo Bioorthogonal Chemistry. ACS Nano (2016) 0.77
Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. ScientificWorldJournal (2014) 0.75
Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment. Biomed Res Int (2013) 0.75
A HSP60-targeting peptide for cell apoptosis imaging. Oncogenesis (2016) 0.75
Biodistribution and SPECT imaging study of (99m)Tc labeling NGR peptide in nude mice bearing human HepG2 hepatoma. Biomed Res Int (2014) 0.75
Hyperspectral and multispectral bioluminescence optical tomography for small animal imaging. Phys Med Biol (2005) 3.11
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res (2004) 2.46
Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med (2004) 2.26
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med (2004) 2.05
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging (2004) 1.76
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol (2004) 1.72
Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med (2002) 1.72
Tetrazine-trans-cyclooctene ligation for the rapid construction of 18F labeled probes. Chem Commun (Camb) (2010) 1.69
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med (2002) 1.60
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging (2004) 1.60
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology (2002) 1.53
Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res (2006) 1.52
Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ₃ targeted PET tracer based on a cyclic RGD peptide. Bioorg Med Chem Lett (2011) 1.36
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist (2009) 1.25
The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition. J Biol Chem (2010) 1.25
Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev (2010) 1.24
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (2012) 1.19
Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets. J Nucl Med (2013) 1.19
Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One (2012) 1.18
Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol (2002) 1.16
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression. Eur J Nucl Med Mol Imaging (2007) 1.13
Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res (2013) 1.10
Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging (2005) 1.10
Automated synthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module. Nucl Med Biol (2010) 1.09
Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression. Bioconjug Chem (2010) 1.08
Tumor quantification in clinical positron emission tomography. Theranostics (2013) 1.06
Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging (2004) 1.05
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med (2013) 1.02
Rapid aqueous [18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun (Camb) (2011) 1.02
[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med (2008) 1.01
Efficient 18F labeling of cysteine-containing peptides and proteins using tetrazine-trans-cyclooctene ligation. Mol Imaging (2013) 1.01
An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol (2009) 1.00
[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr (2007) 0.99
[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol (2008) 0.99
Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling. Dalton Trans (2009) 0.98
Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials (2013) 0.98
Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: facile generation of positron emission tomography/fluorescence dual modality agents for tumor imaging. Theranostics (2013) 0.95
Musculoskeletal system. Semin Nucl Med (2004) 0.95
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med (2013) 0.92
Receptor mediated uptake of a radiolabeled contrast agent sensitive to beta-galactosidase activity. Nucl Med Biol (2003) 0.91
A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano (2014) 0.90
Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm (2012) 0.90
Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med (2007) 0.89
Biglycan overexpression on tooth enamel formation in transgenic mice. Anat Rec (Hoboken) (2008) 0.89
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin Nucl Med (2008) 0.88
RGD-based PET tracers for imaging receptor integrin αv β3 expression. J Labelled Comp Radiopharm (2013) 0.88
2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol (2006) 0.88
FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep (2003) 0.87
18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun (2006) 0.87
The improved syntheses of 5-substituted 2'-[18F]fluoro-2'-deoxy-arabinofuranosyluracil derivatives ([18F]FAU, [18F]FEAU, [18F]FFAU, [18F]FCAU, [18F]FBAU and [18F]FIAU) using a multistep one-pot strategy. Nucl Med Biol (2011) 0.87
Evaluation of 2'-deoxy-2'-flouro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo. Mol Imaging (2003) 0.87
Trackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging. Theranostics (2011) 0.87
A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. Amino Acids (2011) 0.86
Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment. Mol Imaging Biol (2012) 0.86
Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals. Chemistry (2011) 0.86
"Kit like" (18)F labeling method for synthesis of RGD peptide-based PET probes. Am J Nucl Med Mol Imaging (2013) 0.86
Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol Imaging Biol (2006) 0.85
Synthesis and evaluation of 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression. J Nucl Med (2004) 0.85
Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol Imaging Biol (2012) 0.84
Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide. Bioconjug Chem (2011) 0.84
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. J Nucl Med (2012) 0.84
Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging (2009) 0.83
Patlak image estimation from dual time-point list-mode PET data. IEEE Trans Med Imaging (2014) 0.83
Sparsity Constrained Mixture Modeling for the Estimation of Kinetic Parameters in Dynamic PET. IEEE Trans Med Imaging (2013) 0.83
Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nucl Med Biol (2004) 0.82
(64)Cu labeled AmBaSar-RGD2 for micro-PET imaging of integrin αvβ3 expression. Curr Radiopharm (2011) 0.82
Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Mol Pharm (2012) 0.82
In vivo near-infrared fluorescence imaging of integrin α2β1 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe. J Nucl Med (2011) 0.82
Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol (2007) 0.82
Evaluation of ¹⁸F-labeled BODIPY dye as potential PET agents for myocardial perfusion imaging. Nucl Med Biol (2013) 0.81
Novel α(2)β(1) integrin-targeted peptide probes for prostate cancer imaging. Mol Imaging (2011) 0.81
The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals. Theranostics (2012) 0.81
Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res (2003) 0.81
The in vivo effect of propranolol on cerebral perfusion and hypoxia after traumatic brain injury. J Trauma (2009) 0.80
Efficient synthesis of fluorescent-PET probes based on [¹⁸F]BODIPY dye. Chem Commun (Camb) (2014) 0.80
MicroPET imaging of CD13 expression using a (64)Cu-labeled dimeric NGR peptide based on sarcophagine cage. Mol Pharm (2014) 0.79
EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab. Mol Pharm (2013) 0.79
Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer. Eur J Nucl Med Mol Imaging (2011) 0.79
Lesion detection in dynamic FDG-PET using matched subspace detection. IEEE Trans Med Imaging (2009) 0.79
Biodistribution and PET imaging of [(18)F]-fluoroadenosine derivatives. Nucl Med Biol (2007) 0.79
In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature. Amino Acids (2014) 0.79
Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models. Mol Cancer Ther (2013) 0.78
In vivo effect of propranolol dose and timing on cerebral perfusion after traumatic brain injury. J Trauma (2010) 0.78
Axl-targeted cancer imaging with humanized antibody h173. Mol Imaging Biol (2014) 0.78
B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. Radiology (2008) 0.77
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun (2011) 0.77
Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the Joint Working Group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Am Coll Radiol (2005) 0.77
2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol (2006) 0.77
β-adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury. J Trauma Acute Care Surg (2012) 0.77
Radioactive smart probe for potential corrected matrix metalloproteinase imaging. Bioconjug Chem (2012) 0.77
Controlling familywise error rate for matched subspace detection in dynamic FDG PET. IEEE Trans Med Imaging (2009) 0.77
Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([18F]-FMAU). Nucl Med Biol (2012) 0.77